Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/121168
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Santacruz, Rodrigo | - |
dc.contributor.author | Villamor i Casas, Neus | - |
dc.contributor.author | Aymerich Gregorio, Marta | - |
dc.contributor.author | Martínez Trillos, Alejandra | - |
dc.contributor.author | López, Cristina | - |
dc.contributor.author | Navarro López, Alba | - |
dc.contributor.author | Rozman, María | - |
dc.contributor.author | Beà Bobet, Sílvia M. | - |
dc.contributor.author | Royo Moreno, Cristina | - |
dc.contributor.author | Cazorla, Maite | - |
dc.contributor.author | Colomer Pujol, Dolors | - |
dc.contributor.author | Giné Soca, Eva | - |
dc.contributor.author | Pinyol, Magda | - |
dc.contributor.author | Puente, Xose S. | - |
dc.contributor.author | López-Otin, Carlos | - |
dc.contributor.author | Campo Güerri, Elias | - |
dc.contributor.author | López Guillermo, Armando | - |
dc.contributor.author | Delgado, Julio (Delgado González) | - |
dc.date.accessioned | 2018-03-27T15:27:41Z | - |
dc.date.available | 2018-03-27T15:27:41Z | - |
dc.date.issued | 2014-05 | - |
dc.identifier.issn | 0390-6078 | - |
dc.identifier.uri | http://hdl.handle.net/2445/121168 | - |
dc.description.abstract | A proportion of patients with chronic lymphocytic leukemia achieve a minimal residual disease negative status after therapy. We retrospectively evaluated the impact of minimal residual disease on the outcome of 255 consecutive patients receiving any front-line therapy in the context of a detailed prognostic evaluation, including assessment of IGHV, TP53, NOTCH1 and SF3B1 mutations. The median follow-up was 73 months (range, 2-202) from disease evaluation. The median treatment-free survival durations for patients achieving a complete response without or with minimal residual disease, a partial response and no response were 76, 40, 11 and 11 months, respectively (P<0.001). Multivariate analysis revealed that three variables had a significant impact on treatment-free survival: minimal residual disease (P<0.001), IGHV status (P<0.001) and β2-microglobulin levels (P=0.012). With regards to overall survival, factors predictive of an unfavorable outcome were minimal residual disease positivity (P=0.014), together with advanced age (P<0.001), unmutated IGHV status (P=0.001), TP53 mutations (P<0.001) and elevated levels of β2-microglobulin (P=0.003). In conclusion, for patients requiring front-line therapy, achievement of minimal residual disease negativity is associated with significantly prolonged treatment-free and overall survival irrespective of other prognostic markers or treatment administered. | - |
dc.format.extent | 8 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Ferrata Storti Foundation | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3324/haematol.2013.099796 | - |
dc.relation.ispartof | Haematologica, 2014, vol. 99, num. 5, p. 873-880 | - |
dc.relation.uri | https://doi.org/10.3324/haematol.2013.099796 | - |
dc.rights | (c) Ferrata Storti Foundation, 2014 | - |
dc.source | Articles publicats en revistes (Fonaments Clínics) | - |
dc.subject.classification | Leucèmia limfocítica crònica | - |
dc.subject.classification | Biologia molecular | - |
dc.subject.classification | Limfomes | - |
dc.subject.other | Chronic lymphocytic leukemia | - |
dc.subject.other | Molecular biology | - |
dc.subject.other | Lymphomas | - |
dc.title | The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy. | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 646638 | - |
dc.date.updated | 2018-03-27T15:27:41Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 24700492 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Fonaments Clínics) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
646638.pdf | 891.48 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.